Get In Touch

The global vaccine market is expected to expand at a visibly fast pace in the years to follow. The need for immunizing people from several types of diseases and infections has created fresh opportunities for growth within the global market. Vaccines are developed after a rigorous process of testing and analysis, and are even tested for several years. The post-trial stage of vaccines is the most critical phase which decides on the success and adoption rate of the newly-developed antigen. The presence of a seamless medical research sector has created humongous demand within the global vaccine market. The need for preventing people from measles, malaria, polio, and other diseases has given an impetus to the growth of the market.

  • The growth of the global vaccine market over the next decade shall be defined by developments in the field of Covid-19 management. The outbreak of the novel coronavirus has taken the medical and healthcare industries by storm, and has created humongous opportunities for market growth and maturity. However, there has been little success in developing vaccines against the virus. Investments in medical research and diagnosis shall create fresh opportunities for expansion across the global vaccines market. The medical industry is currently testing available vaccines against the coronavirus. There has been some success in averting the virus with the help of existing vaccines.
  • Several research laboratories have ramped up their vaccine development budget to expedite the process of Covid-19 management and research. Government have prioritized the development of new research labs and facilities that will focus on developing vaccines against the coronavirus. Countries such as China and the US are expected to invest in new testing and research facilities for Covid-19 management. There is little doubt that the global vaccines market could clock in humongous revenues due to the outbreak of the coronavirus disease.

U.S. Vaccine Market: Snapshot

The overall vaccine industry has strengthened itself in terms of its growth rate, with a relatively higher growth rate than most other healthcare market segments. Vaccination has been an invaluable addition to better public health, and has helped millions of children, adults and animals from deadly diseases. The CDC stated in a report that diseases such as diphtheria, polio, and smallpox have been fully eliminated, while measles, tetanus, and rubella are some of the disease that have been greatly controlled within the U.S., through timely administration of vaccines. Thus, vaccination is considered as the most effective form of all preventive measures.

The U.S. vaccine market is projected to expand at a CAGR of 4.3% from 2014 to 2020.

Education and Awareness Bode Well for Vaccination Rates

The U.S. human vaccine market is expected to expand swiftly owing to drivers such as the lowered risk of serious and fatal side effects with vaccination, increasing awareness regarding vaccination among common people as well as healthcare providers, federal government’s strict recommendations for immunization against certain diseases, and growing demand for adult vaccines. Similarly, the U.S. animal vaccine market is likely to be propelled by the rising incidence rates of zoonotic diseases and the growing risk factor of animal to human transfer of diseases and infections. The rate of pet adoptions is also rising, especially in urban locations, along with a growth in the consumption rate of poultry products and meat. Over the recent past, a number of remarkable animal vaccines have made it through the pipeline and past approvals, including Once PMH IN and Prime Pac PRRS+ further improving the growth rate of this market.

However, increasingly strict guidelines and regulations for the lengthy and time consuming approval process has resulted in the increase in cost of several new vaccines. The development efforts on future pipeline vaccines is also slowing down due to the high costs of development, thereby restraining the U.S. human vaccine market. The manufacturers and distributors of both human and animal vaccines also face the issues related to storage, handling, and transportation of vaccines. Manufacturers require heavy usage of cold storage chains for over 90% of all vaccines currently produced, in order to prevent loss of potency and efficacy by exposure to higher temperatures, considerably increasing the costs of transportation and equipment maintenance.

Pneumococcal Vaccines to Top Charts Till 2020

The U.S. human vaccine market can be classified into pediatric and adult vaccines, in terms of the type of vaccines. Based on antigens, the U.S. human vaccine market has been categorized into hepatitis, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), combination vaccines and others. Among these, combination vaccines market had represented the leading antigen segment in human vaccines for 2013, based on revenue generation.

The animal vaccines market in the U.S. have been segmented into livestock and companion vaccines. The latter segment is further categorized into canine and feline, while livestock vaccines segment can be been segmented into ovine, poultry, porcine, bovine, and equine. Canine vaccines took a relatively larger share than the feline vaccines in 2013, in terms of revenue, due to the higher average cost of canine vaccinations.

The U.S. human vaccine market is dominated by players such as GlaxoSmithKline PLC, Sanofi, Pfizer, Ltd., Merck & Co., Inc., and Novartis International AG. These players have successfully cornered critical areas of the market through the introduction of innovative vaccines and new ones in the pipeline. Zoetis, Inc., Merck & Co., Inc. (Merck Animal Health), Sanofi (Merial, animal health division of Sanofi) and Boehringer Ingelheim are the key companies in the U.S. animal vaccine market.

A vaccine is a biological preparation of killed forms of microbes, living attenuated organisms, living fully virulent organisms, a microbe’s toxins or one of its surface proteins. Vaccines play a key role in improving immunity against particular diseases. Therefore, vaccination is promoted as a vital public health intervention throughout the globe. According to the World Health Organization (WHO), vaccination has reduced the burden of infectious disease globally to a great extent. According to a study conducted by Zhou et al, vaccination prevented 42,000 early deaths and approximately 20 million cases of diseases in children born in the U.S. in 2009, resulting in saving USD 13.5 billion in direct medical and non-medical costs and USD 68.8 billion in total societal costs. 
 
This report on the U.S. vaccine market offers an insightful and in-depth assessment of the current as well as future market potential of human as well as animal vaccine markets. The human vaccine market is further segmented into pediatric and adult vaccine markets, based on vaccine type. On the basis of different antigens, the U.S. human vaccine market has been categorized into hepatitis, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), combination vaccines and others. The U.S. animal vaccine market is broadly segmented as companion animal and livestock vaccine markets. The U.S. companion animal vaccine market segment has been further categorized into canine and feline, while the livestock vaccine market has been divided into porcine, bovine, ovine, poultry and equine markets.
 
Each of these segments and sub-segments has been extensively analyzed in the report, considering factors such as market trends, recent developments, future outlook and opportunities. The report provides market revenue size in terms of USD million for each segment and sub-segment for the period 2012 to 2020. In addition, the compounded annual growth rate (CAGR) of the overall U.S. vaccine market and various segments and sub-segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. Extensive pricing analysis for human as well as animal vaccine market has been provided in the report.
 
This report includes an elaborate executive summary, which covers a market snapshot representing key findings from the study on the U.S. vaccine market. The market overview section of the report on the U.S. vaccine market comprises qualitative analysis of the overall market considering factors determining market dynamics such as growth drivers, restraints and opportunities. The market overview chapter also includes a section describing the vaccine approval and regulatory pathway in the U.S. The competitive landscape section has been provided for both human and animal vaccine markets. This section presents the market revenue share of key players in terms of percentage for the year 2013. The market share analysis of key players involved the study of company product portfolio and sales revenue along with market developments such as new product launch and regulatory approvals.
 
This study on the U.S. vaccine market suggests a list of recommendations for new companies willing to enter the market and for existing companies to accentuate revenue shares, which is likely to help in the decision-making process. The report concludes with the profiles of major players in the U.S. vaccine market such as GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Pfizer, Ltd., Sanofi, Boehringer Ingelheim and Zoetis, Inc. Each company profile in the report contains information such as company overview, financial overview, product portfolio, business strategies and recent developments. The company overview section comprises basic information about the company such as major business areas, company’s brief history and its establishment year, number of employees and geographical presence. In the financial overview section, information such as selling and general administrative expenses, R&D expenses and annual revenue for the last three consecutive years (2011, 2012 and 2013) has been provided. The business strategies section mentions key strategies adopted by the company in the past to strengthen its position in the vaccine market. The recent development section gives information about the recent happening in the company related with the vaccine market.
 
The U.S. vaccine market is segmented as follows:
 
U.S. Human Vaccine Market, by Type
  • Pediatric
  • Adult
U.S. Human Vaccine Market, by Antigen
  • Hepatitis (A & B)
  • Influenza
  • Meningococcal
  • Pneumococcal
  • Human Papillomavirus (HPV)
  • Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
  • Others
U.S. Animal Vaccine Market, by Animal Type
  • Companion Animal Vaccine Market
    • Canine
    • Feline
  • Livestock Vaccine Market
    • Porcine
    • Bovine
    • Ovine
    • Poultry
    • Equine

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

 
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Assumptions
      1.3.2 Sources
              1.3.2.1 Secondary Research
              1.3.2.2 Primary Research
      1.3.3 Models
 
Chapter 2 Executive Summary
2.1 Market Snapshot: U.S. Vaccine Market (2013 & 2020)
2.2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
 
Chapter 3 U.S. Vaccine Market Overview
3.1 Introduction
3.2 Vaccine Approval Regulatory Pathway
      3.2.1 Major Steps: Vaccine Development and Commercialization
3.3 Drivers
      3.3.1 Growing incidence of zoonotic diseases drives increased animal vaccination
      3.3.2 Increasing consumption of chicken to augment the demand of poultry vaccines in the U.S.
      3.3.3 Extremely low risk of serious and fatal side effects associated with vaccines is a strong driver in the adoption of vaccines
      3.3.4 Education and awareness through various governmental and non-profit organizations
3.4 Restraints
      3.4.1 Strict regulatory pathway and high cost associated with new vaccine discovery and development
      3.4.2 High cost associated with vaccine transportation, storage and handling
3.5 Opportunities
      3.5.1 DNA vaccines hold immense potential for a number of human and animal diseases
      3.5.2 The U.S. offers immense potential for adult vaccines market
3.6 Competitive Landscape
      3.6.1 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
      3.6.2 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
 
Chapter 4 U.S. Human Vaccine Market Revenue
4.1 Overview
      4.1.1 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million)
      4.1.2 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million)
      4.1.3 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
      4.1.4 Hepatitis
              4.1.4.1 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.5 Influenza
              4.1.5.1 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.6 Meningococcal 
              4.1.6.1 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.7 Pneumococcal
              4.1.7.1 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.8 Human Papillomavirus (HPV)
              4.1.8.1 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.9 Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
              4.1.9.1 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.10 Others
               4.1.10.1 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)
4.2 Pricing Analysis
      4.2.1 Pricing Analysis: Hepatitis Vaccines
      4.2.2 Pricing Analysis: Influenza Vaccines
      4.2.3 Pricing Analysis: Meningococcal Vaccines
      4.2.4 Pricing Analysis: Pneumococcal Vaccines
      4.2.5 Pricing Analysis: Human Papillomavirus Vaccines (HPV)
      4.2.6 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
      4.2.7 Pricing Analysis: Other Vaccines
 
Chapter 5 U.S. Animal Vaccine Market Revenue, 2012 – 2020 (USD Million)
5.1 Overview
      5.1.1 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million)
      5.1.2 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %)
5.2 Companion Animal Vaccines
      5.2.1 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
      5.2.2 Canine Vaccines
              5.2.2.1 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.2.2.2 Pricing Analysis: Canine Vaccines
      5.2.3 Feline Vaccines
              5.2.3.1 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.2.3.2 Pricing Analysis: Feline Vaccines
5.3 Livestock Vaccines
      5.3.1 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
      5.3.2 Porcine Vaccines
              5.3.2.1 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.2.2 Pricing Analysis: Porcine Vaccines
      5.3.3 Bovine Vaccines
              5.3.3.1 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.3.2 Pricing Analysis: Bovine Vaccines
      5.3.4 Ovine Vaccines
              5.3.4.1 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.4.2 Pricing Analysis: Ovine Vaccines
      5.3.5 Poultry Vaccines
              5.3.5.1 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million)
      5.3.6 Equine Vaccines
              5.3.6.1 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.6.2 Pricing Analysis: Equine Vaccines
 
Chapter 6 Recommendations
6.1 Focus on cost-effective vaccine manufacturing
6.2 Focus on developing technologically advanced vaccines such as DNA vaccines
 
Chapter 7 Company Profiles
7.1 Boehringer Ingelheim
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 GlaxoSmithKline plc
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Merck & Co., Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Novartis International AG
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Pfizer, Inc.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Sanofi SA
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Zoetis, Inc.
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
List of Tables
 
TABLE 1 Market Snapshot: U.S. Vaccine Market (2013 & 2020)
TABLE 2 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million)
TABLE 3 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million)
TABLE 4 Pricing Analysis: Hepatitis Vaccines
TABLE 5 Pricing Analysis: Influenza Vaccines
TABLE 6 Pricing Analysis: Meningococcal Vaccines
TABLE 7 Pricing Analysis: Pneumococcal Vaccines
TABLE 8 Pricing Analysis: Human Papillomavirus Vaccines (HPV)
TABLE 9 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
TABLE 10 Pricing Analysis: Other Vaccines
TABLE 11 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million)
TABLE 12 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
TABLE 13 Pricing Analysis: Canine Vaccines
TABLE 14 Pricing Analysis: Feline Vaccines
TABLE 15 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
TABLE 16 Pricing Analysis: Porcine Vaccines
TABLE 17 Pricing Analysis: Bovine Vaccines
TABLE 18 Pricing Analysis: Ovine Vaccines
TABLE 19 Pricing Analysis: Equine Vaccines
TABLE 20 Boehringer Ingelheim: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 21 GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 22 Merck & Co., Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 23 Novartis International AG: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 24 Pfizer, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 25 Sanofi SA: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 26 Zoetis, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
List of Figures
 
FIG. 1 U.S. Vaccine: Market Segmentation
FIG. 2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
FIG. 3 Major Steps: Vaccine Development and Commercialization
FIG. 4 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 5 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 6 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
FIG. 7 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %)
FIG. 15 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Boehringer Ingelheim Vetmedica: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 23 GlaxoSmithKline plc: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 24 Merck & Co., Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 25 Novartis International AG: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 26 Pfizer, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 27 Sanofi SA: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 28 Zoetis, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Us Vaccine Market